{"title":"肥胖和 2 型糖尿病患者代谢功能障碍相关性脂肪肝 (MASLD) 的患病率：一项横断面研究。","authors":"Saba Latif, Tasnim Ahsan","doi":"10.5005/jp-journals-10018-1437","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important entity in patients with type-2 diabetes (T2D). Exploring the prevalence and related factors of MASLD is vital toward developing effective methods of diagnosis and treatment. The objective of this study was to determine the prevalence of MASLD in persons with obesity and T2D.</p><p><strong>Materials and methods: </strong>This cross-sectional study was conducted at a private healthcare facility (Medicell Clinics) in Karachi, Pakistan, reviewing records from January to December 2022. Persons of either gender aged 18 or above with a diagnosis of T2D and/or obesity were analyzed.</p><p><strong>Results: </strong>Of a total of 646 persons, 430 (66.6%) were females. The mean age was 48.58 ± 13.88 years, ranging between 18 and 85 years. T2D was noted in 351 (54.3%) patients, while obesity was observed in 593 (91.8%) persons, 396 (61.3%) had MASLD. Persons having MASLD had significantly higher body mass index (31.16 ± 5.13 vs 28.14 ± 4.76 kg/m<sup>2</sup>, <i>p</i> < 0.001). Likewise, obesity was significantly associated with MASLD (94.9 vs 86.8%, <i>p</i> < 0.001). The odds ratios (OR) and 95% confidence intervals (CIs) are reported in multivariate logistic regression table. Persons with T2DM (OR = 1.519, <i>p</i> = 0.009), and obesity (OR = 2.651, <i>p</i> = 0.001) showed significantly increased odds of having MASLD. The analysis revealed that individuals in the age-group of 18-40 (OR = 1.627, <i>p</i> = 0.014) had increased odds of having MASLD.</p><p><strong>Conclusion: </strong>The prevalence of MASLD was very high in persons with T2D, and obesity. Type-2 diabetes with or without obesity, or the other way around, significantly increases the risk of MASLD. Therefore, these persons should be screened for MASLD to improve clinical outcomes in the affected people.</p><p><strong>How to cite this article: </strong>Latif S, Ahsan T. Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study. Euroasian J Hepato-Gastroenterol 2024;14(2):129-133.</p>","PeriodicalId":516317,"journal":{"name":"Euroasian journal of hepato-gastroenterology","volume":"14 2","pages":"129-133"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714111/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study.\",\"authors\":\"Saba Latif, Tasnim Ahsan\",\"doi\":\"10.5005/jp-journals-10018-1437\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important entity in patients with type-2 diabetes (T2D). Exploring the prevalence and related factors of MASLD is vital toward developing effective methods of diagnosis and treatment. The objective of this study was to determine the prevalence of MASLD in persons with obesity and T2D.</p><p><strong>Materials and methods: </strong>This cross-sectional study was conducted at a private healthcare facility (Medicell Clinics) in Karachi, Pakistan, reviewing records from January to December 2022. Persons of either gender aged 18 or above with a diagnosis of T2D and/or obesity were analyzed.</p><p><strong>Results: </strong>Of a total of 646 persons, 430 (66.6%) were females. The mean age was 48.58 ± 13.88 years, ranging between 18 and 85 years. T2D was noted in 351 (54.3%) patients, while obesity was observed in 593 (91.8%) persons, 396 (61.3%) had MASLD. Persons having MASLD had significantly higher body mass index (31.16 ± 5.13 vs 28.14 ± 4.76 kg/m<sup>2</sup>, <i>p</i> < 0.001). Likewise, obesity was significantly associated with MASLD (94.9 vs 86.8%, <i>p</i> < 0.001). The odds ratios (OR) and 95% confidence intervals (CIs) are reported in multivariate logistic regression table. Persons with T2DM (OR = 1.519, <i>p</i> = 0.009), and obesity (OR = 2.651, <i>p</i> = 0.001) showed significantly increased odds of having MASLD. The analysis revealed that individuals in the age-group of 18-40 (OR = 1.627, <i>p</i> = 0.014) had increased odds of having MASLD.</p><p><strong>Conclusion: </strong>The prevalence of MASLD was very high in persons with T2D, and obesity. Type-2 diabetes with or without obesity, or the other way around, significantly increases the risk of MASLD. Therefore, these persons should be screened for MASLD to improve clinical outcomes in the affected people.</p><p><strong>How to cite this article: </strong>Latif S, Ahsan T. Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study. Euroasian J Hepato-Gastroenterol 2024;14(2):129-133.</p>\",\"PeriodicalId\":516317,\"journal\":{\"name\":\"Euroasian journal of hepato-gastroenterology\",\"volume\":\"14 2\",\"pages\":\"129-133\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714111/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Euroasian journal of hepato-gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5005/jp-journals-10018-1437\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Euroasian journal of hepato-gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10018-1437","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景：代谢功能障碍相关脂肪变性肝病（MASLD）是2型糖尿病（T2D）患者的重要疾病。探讨MASLD的患病率及其相关因素对于制定有效的诊断和治疗方法至关重要。本研究的目的是确定肥胖和T2D患者中MASLD的患病率。材料和方法：本横断面研究在巴基斯坦卡拉奇的一家私人医疗机构（Medicell诊所）进行，回顾了2022年1月至12月的记录。年龄在18岁或以上，诊断为T2D和/或肥胖的男女皆可。结果：646例患者中，女性430例，占66.6%。年龄18 ~ 85岁，平均48.58±13.88岁。351例（54.3%）患者出现T2D， 593例（91.8%）患者出现肥胖，396例（61.3%）患者出现MASLD。MASLD患者的身体质量指数明显较高（31.16±5.13 vs 28.14±4.76 kg/m2, p < 0.001）。同样，肥胖与MASLD显著相关（94.9% vs 86.8%, p < 0.001）。在多元logistic回归表中报告比值比（OR）和95%置信区间（CIs）。T2DM （OR = 1.519, p = 0.009）和肥胖（OR = 2.651, p = 0.001）患者发生MASLD的几率显著增加。分析显示，18-40岁年龄组的个体（OR = 1.627, p = 0.014）患MASLD的几率增加。结论：t2dm、肥胖人群中MASLD患病率较高。2型糖尿病伴或不伴肥胖，或相反，显著增加MASLD的风险。因此，应该对这些人进行MASLD筛查，以改善患者的临床结果。Latif S, Ahsan T.肥胖和2型糖尿病患者代谢功能障碍相关脂肪变性肝病（MASLD）患病率：一项横断面研究。中华肝病与胃肠病杂志；2009;14(2):129-133。
Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important entity in patients with type-2 diabetes (T2D). Exploring the prevalence and related factors of MASLD is vital toward developing effective methods of diagnosis and treatment. The objective of this study was to determine the prevalence of MASLD in persons with obesity and T2D.
Materials and methods: This cross-sectional study was conducted at a private healthcare facility (Medicell Clinics) in Karachi, Pakistan, reviewing records from January to December 2022. Persons of either gender aged 18 or above with a diagnosis of T2D and/or obesity were analyzed.
Results: Of a total of 646 persons, 430 (66.6%) were females. The mean age was 48.58 ± 13.88 years, ranging between 18 and 85 years. T2D was noted in 351 (54.3%) patients, while obesity was observed in 593 (91.8%) persons, 396 (61.3%) had MASLD. Persons having MASLD had significantly higher body mass index (31.16 ± 5.13 vs 28.14 ± 4.76 kg/m2, p < 0.001). Likewise, obesity was significantly associated with MASLD (94.9 vs 86.8%, p < 0.001). The odds ratios (OR) and 95% confidence intervals (CIs) are reported in multivariate logistic regression table. Persons with T2DM (OR = 1.519, p = 0.009), and obesity (OR = 2.651, p = 0.001) showed significantly increased odds of having MASLD. The analysis revealed that individuals in the age-group of 18-40 (OR = 1.627, p = 0.014) had increased odds of having MASLD.
Conclusion: The prevalence of MASLD was very high in persons with T2D, and obesity. Type-2 diabetes with or without obesity, or the other way around, significantly increases the risk of MASLD. Therefore, these persons should be screened for MASLD to improve clinical outcomes in the affected people.
How to cite this article: Latif S, Ahsan T. Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study. Euroasian J Hepato-Gastroenterol 2024;14(2):129-133.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
